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Crosstalk between immunity and metabolism
	The immune system is constituted of a heterogeneous population of immune cells which are able to respond to inflammatory stimuli upon switching from a quiescent to an activated status. These responses are tightly regulated by a wide range of cell type specific receptors and transcription factors. In immune cells this determines changes in the expression of large numbers of genes and results in the acquisition of new functions, such as the production of cytokines, lipid mediators and metabolites as well as the ability to proliferate, differentiate into specialized subtypes and migrate to target tissues. All such functions require the supply of nutrients into different metabolic pathways. In the last few years there has been an increasing appreciation of how such metabolic pathways integrate with and in fact determine specific immune cell responses (1). 

T-cell metabolism, inflammation and autoimmunity
	In the past few years metabolism has been in the spotlight because of its pivotal role in disorders such as cancer as well as inflammatory and autoimmune diseases. Many studies have highlighted how cancer cells rely upon bioenergetic pathways to support their growth. As for cancer cells, immune cells also adapt their metabolic status as a consequence to changes in the external microenvironment (i.e. inflammation). T cells are key players of adaptive immunity and have high metabolic demand for their activation, proliferation, differentiation in specific cell subsets and migration to target organs, while quiescent T cells rely mainly upon fatty acid oxidation and mitochondrial respiration to fuel their energy demand (2, 3). In response to antigens, proliferating T cells up-regulate their glycolytic flux and the glucose transporter GLUT1, resulting in the bio-synthesis of proteins, nucleic acids and lipids that are essential for their activation and effector functions (4, 5). Conversely, memory T cells and/or chronically activated T cells do not proliferate and do not require high energy demand. Indeed, they mainly utilise oxidative phosphorylation (OXPHOS) to produce the required amounts of ATP (2, 3).
	Effector CD4+ T cells have the ability to differentiate into Th1 (helper) cells promoting cell-mediated immunity, Th2 cells supporting the humoral immune response, Th17 cells promoting mucosal immunity or regulatory T (Treg) cells suppressing effector T-cell function (6, 7). In contrast to Th cells, which increase glycolysis over mitochondrial metabolism, Treg cells and memory T cells display a metabolic program involving mainly lipid oxidation and OXPHOS (8). This suggests that T cells undergo metabolic reprogramming according to their differentiation state. Alterations of this fine tuning between metabolism and immunity might lead to an unbalance between pro- and anti-inflammatory responses and to the establishment of a non-resolving-inflammatory environment, chronic inflammation and autoimmunity (9). 
	Several studies have highlighted the molecular mechanisms that govern metabolic reprogramming in the immune system in tumours; however, their role in autoimmunity is still unclear (10). There is increasing evidence that chronically stimulated autoreactive T cells preferentially meet their metabolic demands through mitochondrial OXPHOS rather than aerobic glycolysis (8, 11). For instance, murine studies have shown that autoreactive splenocytes from lupus-prone mice preferentially convert glucose to CO2, increasing mitochondrial metabolism for ATP synthesis (12). Studies in humans also revealed that patients with autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) display defects in metabolic pathways such as glycolysis and mitochondrial oxidative metabolism (13). Indeed, clinical, epidemiological and experimental data have suggested that the pathogenesis of several immune-mediated disorders might involve factors, hormones and neural mediators that link metabolism and immune system (14, 15). In this regard, the discovery of leptin, one of the most abundant adipocyte-derived hormones controlling food intake and metabolism, has suggested that an organism’s nutritional status can control immune self-tolerance (16). Recently, metabolites, such as succinate, citrate and lactate, all intermediate and end products of metabolic pathways, have been shown to activate signalling, resulting in the modulation of immune functions (17-19).

Lactate bridges metabolism, inflammation and cancer
	Lactate is a ubiquitous metabolite, found for the first time in the mammalian body at the beginning of the 20th century (20). Lactate production occurs mainly in the cell cytoplasm under hypoxic conditions, or as a consequence of high flux of glycolysis in proliferating cells via lactate dehydrogenase (LDH), an enzyme which also regenerates the reduced form of nicotinamide adenine dinucleotide (NADH) (21). ATP generation via glycolysis is much less efficient than that via OXPHOS (i.e. 2 moles versus 36 moles of ATP produced per mole of glucose via glycolysis versus OXPHOS respectively). Therefore activated immune and cancer cells relying mainly upon glycolysis need to increase their uptake of glucose to remain viable and functional (22, 23). This selective utilisation of glycolysis even in the presence of oxygen is known as ‘aerobic glycolysis’ or the ‘Warburg Effect’ and although it was originally referred only to the peculiar metabolism adopted by rapidly proliferating cancer cells, it has since been observed in specialised immune cells such as lymphocytes and macrophages (18, 24). As a consequence of hypoxic or aerobic glycolysis, lactate is produced and accumulates in the extracellular space. With a pKa of 3.83, lactate is present in solution either as the acid in its undissociated form (i.e., lactic acid) at low pH or as the ion salt (i.e., sodium lactate) at higher pH. These two molecules can have different effects on target cells, with lactic acid having the confounding factor that its effects might be indirectly due to acidification. CD8+ T-cell migration was shown to be inhibited by lactic acid but not sodium lactate (18). Progressive acidification of the medium containing sodium lactate, which increases the availability of lactic acid, reduced the motility of CD8+ T cells (18). However, neither the presence in the culture media of sodium lactate at a concentration of 10 mM alone nor acidification of the culture media to pH 4.5 with HCl alone had any effects on the motility of CD8+ T cells (18). This suggests that inhibition of CD8+ T-cell motility by lactic acid cannot be simply ascribed to its effect on the acidification of the culture media, in line with findings on the effect of lactate on the motility of macrophages in a tumour environment from Su et al (24). Simultaneous availability of lactate and H+ is necessary to regulate the motility of CD8+ T cells [18]. On the contrary CD4+ T-cell migration was not affected in lactic acid–rich medium, but was inhibited by sodium lactate (18).
	Lactate homeostasis in healthy and cancerous cells requires the presence of lactate transporters on the cell surface. Four members of the solute carrier 16a family of 12-membrane pass, proton-linked monocarboxylic acid symporters, i.e. MCT1 (also known as SLC16A1), MCT2 (also known as SLC16A7), MCT3 (also known as SLC16A8), and MCT4 (also known as SLC16A3), and two sodium-coupled lactate cotransporters (SLC5A12, SLC5A8) have been described (25, 26). These channels share conserved sequence motifs and have different affinity for sodium lactate, lactic acid and other monocarboxylates. The transport depends on pH, intra- and extracellular lactate concentration as well as other substrates such as pyruvate, butyrate, etc. (27, 28). Samuvel et al reported that alpha-cyano-4-hydroxycinnamic acid, an inhibitor of monocarboxylate transporters, blocks lactate-augmented inflammatory gene expression and NF-kappaB activity in human macrophages, indicating that lactate transport through monocarboxylate transporters is required for macrophage effector functions (29). Besides MCTs, proton-sensing GPCRs such as T-cell death-associated gene 8 (TDAG8) have been shown to be important for the modulation of T cells in an acidic tumour environment and during inflammation (30, 31). 
	A feature of tumour and inflammatory sites is the accumulation of lactic acid due to enhanced glycolysis. Here lactic acid has been shown to suppress the proliferation and cytokine production of human cytotoxic T lymphocytes (CTLs) in cancer patients (32) as well as their migratory abilities (18). This effect is partly explained by lactate’s involvement in inhibiting TCR-triggered phosphorylation of JNK, c-Jun and p38, which is implicated in IFN-γ production (33). Along the same lines, a recent paper by Colegio et al. shows that tumour-associated macrophages (TAMs) can also ‘sense’ metabolic changes typical of the malignant state (23). In the tumour microenvironment, cancer cells produce high amounts of lactic acid, which are extruded in the intercellular space via MCT4. Released lactic acid is then taken up by tumour-associated macrophages via MCT1, promoting in turn macrophage polarisation toward a TAM phenotype via the induction of hypoxia inducible factor 1 (HIF-1) and arginase 2. These effects induce vascular endothelial growth factor (VEGF) production and ultimately support tumour growth in a feed forward loop (23). Moreover, TNF secretion by human monocytes was found to be suppressed in the presence of high lactate concentration and reduced pH in tumour microenvironment (34). Notably, neutralising tumour acidity with bicarbonate monotherapy impaired the growth of some cancer types (30 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Pilon-Thomas%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26719539​)). Similarly, another study pointed to the role of lactic acid in the TAM regulation of the epithelial-to-mesenchymal transition (24). 
	Targeting lactate transporters has become a promising therapeutic avenue in oncology. A recent study found that blocking the lactate transporter MCT1 reduces the proliferation of breast cancer cells co-expressing MCT1 and MCT4 (35) and reduces HIF-1 induced angiogenesis in cervix squamous carcinoma (36, 37). On the other hand, other authors showed that lactate-mediated angiogenesis is independent of HIF-1 but is due to direct binding to NDRG3 during hypoxia (38). This event leads to Raf/ERK1/2 signalling pathway activation and promotes proliferation and angiogenesis (38). LDH, the enzyme that converts pyruvate to lactate, is increased in tumour cells (39, 40). A decreased frequency of myeloid-derived suppressor cells (MDSCs) was observed in the spleens of mice carrying LDH-A-depleted tumours. NK cells isolated from LDH-A-depleted tumours had improved cytolytic function (40). The addition of exogenous lactate increased the frequency of MDSCs generated from murine bone marrow cells and inhibited cytolytic function of both human and murine NK cells in vitro. This reduction of NK-cell cytotoxic activity was accompanied by lower expression of perforin and granzyme. Therefore, tumour-derived lactate hinders NK cell-mediated responses directly via inhibition of cytolytic function as well as indirectly by increasing the numbers of MDSCs inhibiting NK-cell cytotoxicity (40). This evidence is also supported by the recent paper by Brand et al., showing that lactate leads to tumour immune escape by inhibiting the function and survival of T cells and NK cells (41). Along the same lines another study supports the role of LDH-A in tumour maintenance (39). Knocking down LDH-A by short hairpin RNAs resulted in a reduced ability of tumour cells to proliferate under hypoxic conditions. This was accompanied by increased mitochondrial respiration and decrease of mitochondrial membrane potential. The tumourigenicity of the LDH-A-deficient cells was severely diminished, and this phenotype was reversed by complementation with the human LDH-A (39).

 Lactate in autoimmunity – observations from RA
	Lactate is used for several homeostatic functions in the body. Indeed, muscle-derived lactate is used by hepatocytes to fuel hepatic gluconeogenesis while astrocytes/neurons in the brain utilise lactate for oxidative metabolism (42, 43). Lactate levels also increase according to the grade of inflammation. Physiological lactate concentration is actively kept in the range of 1.5–3 mM in blood and tissues of healthy individuals via specific absorption systems in the kidney operated by SLC5A8 and SLC5A12. Lactate levels can, however, rise up to 10 mM in inflammatory pathologies (e.g. rheumatic synovial fluid) and even 30–40 mM in cancerous tissues (18, 23, 27). Accumulation of lactate in the synovial fluid of RA patients has been known for the last 20 years (48), being the result of high synovial cells metabolic demand (18). Specifically, it was suggested that synovial lactate measurement could be a reliable indicator for differentiating inflammatory arthritides (48). A positive correlation between LDH-A, high lactate levels and tumour progression has been widely documented in various tumours. Less is known in autoimmunity. LDH isoenzymes were found higher in serum and synovial fluid of RA compared to osteoarthritis (OA) patients (49). Moreover LDH activity was increased in RA synovial tissues compared to healthy controls thus suggesting an increased glycolytic metabolism in the RA synovial joints (50). The key role of LDH in promoting inflammation was also recently highlighted in the recent paper by Peng et al. where they identified that LDH-A is important to promote T-cell effector functions by increasing acetylation and IFN- transcription (51).
	Lactate transporters are becoming increasingly relevant in the pathogenesis of RA. Indeed, it has been recently found that monocarboxylate lactate transporter 4 (MCT4) is up-regulated by RA synovial fibroblast (RASFs) compared to osteoarthritis (OA) SF. Similar to cancer cells, highly proliferating RASFs overexpress MCT4, thus promoting synovial fluid acidification (52). The silencing of MCT4 inhibited proliferation of RASFs and reduced the severity of arthritis in mice with collagen-induced arthritis (CIA) by inducing apoptosis of synovial cells (52).  This suggests a potential role of MCT4 inhibitors as a novel therapeutic target for RA.
	RA synovitis is a highly heterogeneous chronic disease characterised by peculiar histological patterns. Inflammatory immune cells can be found either randomly distributed within the synovial sublining with a predominant monocyte/macrophage infiltration (myeloid-(M)/diffuse pathotype, 40% of RA patients), or spatially-grouped into follicular structures which acquire features of secondary lymphoid-organs including high-endothelial venules (HEV), T/B-cell-segregation, autoantibody (i.e. anti-cyclic citrullinated peptide(CCP) production and follicular-dendritic cell(FDC)-networks; these are defined as ectopic lymphoid-like structures (lymphoid-(L)/ELS pathotype, 40% of RA patients). A rarer subset, about 20% of RA patients, is characterised by a prevalent fibroid signature (fibroid-(F)/pauci-immune pathotype) (53, 54). In this context, the recognition that ELS development may play a key pathogenic role in autoimmunity and may be exploited as potential biomarker for disease evolution and response to therapy is gaining attention (53, 54).
Although the mechanisms responsible for the preferential accumulation of autoreactive B cells and T cells in ELS are not fully understood, a direct role has been proposed for Epstein–Barr virus (EBV) and IL-17 production by Th17 cells in the development of autoimmunity (53-58). The rheumatoid synovial environment is paradigmatic of all the lactate-induced changes in CD4+ and CD8+ T cells we have recently reported, including retention, IL-17 secretion and loss of antigen responsiveness (18). Inflammatory sites are acidic and hypoxic and this is due at least in part to the abundance of lactate, which is able to modulate the expression of HIF-1, which is an important regulator of T cell differentiation and effector functions. Indeed, HIF-1has been shown to promote the switch towards a Th17 phenotype while inhibiting Treg cell differentiation (59). This might explain a possible mechanism through which lactate enhances IL-17 production during hypoxia. 
We recently showed that SLC5A12 is highly expressed in human RA synovial tissues (ST) (18). Strikingly, its levels significantly increased in correlation with the RA-ST T cell score and with the formation of ELSs, which are rich in IL-17 (18, 57, 58), thus suggesting a possible role of lactate/SLC5A12-induced metabolic signalling network in promoting chronic inflammation in RA (Figure 1). 
	Lactate acts as an immunomodulatory molecule able to control T cell effector functions during inflammation (18). Indeed, unlike in tumours where lactate plays a key role in promoting cancer cell migration and growth, in activated T cells lactate activates a stop migration signal. This phenomenon is due to the interaction of sodium lactate and lactic acid with the transporters SLC5A12 and SLC16A1 which are selectively expressed on the surface of CD4+ and CD8+ subsets, respectively (18). Sodium lactate-mediated inhibition of CD4+ T-cell migration is regulated via lactate interference of the glycolytic pathway which is required for migration in response to chemokine signals (18, 44 (​https:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Dr%C3%B6ge%20W%5BAuthor%5D&cauthor=true&cauthor_uid=3497729​)). This suggests that in a lactate-rich environment T cells undergo a stop migration signal and are actively retained. Indeed, in the presence of sodium lactate, activated CD4+ T cells show a downregulation of glycolytic enzymes such as HK1 and PKM1/2 (18). Sodium lactate also prompts CD4+ T cells to start producing higher amounts of the pro-inflammatory cytokine IL-17 (Figure 1) but not IFN-, while lactic acid causes impairment of CD8+ T cell-mediated killing (18, 45). Previous reports have also shown that lactic acid is a proinflammatory mediator secreted by tumour cells and is able to activate the IL-23/IL-17 proinflammatory pathway but not the T helper 1 pathway (46, 47). All these events might lead to enhanced chronic inflammation (18, Figure 1).	
Taken together lactate plays an important role in inducing and promoting inflammation and in the modulation of immune cell functions. Targeting lactate transporters, LDH, and HIF-1 may represent a novel therapeutic intervention in autoimmune and inflammatory diseases elicited by proinflammatory T cells.

Metabolic dysregulation in RA and other autoimmune conditions
In addition to lactate, evidence supports a wider role for metabolism in the dysregulation of the immune system in autoimmunity. Several studies on glucose metabolism in RA have shown the involvement of glycolytic enzymes in autoimmune responses. Specifically, enolase, aldolase, glucose-6-phosphate isomerase, and adipokines (i.e. leptin and adiponectin) have been identified as potential triggers for the breakdown of self tolerance in both peripheral blood and synovial tissue cells (16, 60). These factors were shown to induce immune cell activation, pro-inflammatory cytokine secretion (i.e. TNF, IL17, IFN) as well as production of autoantibodies (i.e. anti-CCP), leading to autoimmunity and bone destruction (16, 60). 
	Recent elegant studies by the Weyand’s group have shown that in contrast to healthy T cells, naive CD4+ T cells from RA patients are unable to up-regulate the glycolytic key enzyme PFKFB3, thus resulting in a state of energy deprivation and a tendency towards senescence due to defective autophagy. Moreover, RA CD4+ T cells shift their metabolic pathway towards the pentose phosphate pathway (PPP), with up-regulation of glucose-6-phosphate dehydrogenase (G6PD) (61, 62). These events lead to the production of high amount of NADPH (reduced form nicotinamide adenine dinucleotide phosphate), ROS (reactive oxygen species) consumption and altered activation of ataxia telangiectasia mutated (ATM), a key enzyme involved in cell cycle, thus resulting in cell hyper-proliferation, Th1/Th17 differentiation and inflammation (61, 62). Constitutive ATM insufficiency in naïve RA T cells and pharmacologically-driven ATM insufficiency in healthy T cells have been shown to accelerate their conversion into effector memory T cells. ROS reduction and ATM insufficiency cause T-cell mal-differentiation into IFN- and IL-17 effector cells. These abnormalities are reversible via replenishment of the ROS pool with the naphthoquinone menadione, inhibition of the synthesis of the ROS quencher glutathione, or blockade of glucose shunting into the PPP (61, 62).
	In contrast to T cells, synovial RA fibroblasts display an intrinsic ability to employ glycolytic metabolism under metabolic stress. Indeed, glucose deprivation or glycolytic inhibitors impaired their cytokine secretion, proliferation, and migration (63).
	Recently a gas chromatography–mass spectrometry (GC–MS) study, carried out on sera samples, has highlighted a peculiar metabolic signature of RA patients compared to healthy controls (64). Specifically, RA patients displayed decreased levels of amino acids (leucine, phenylalanine, pyroglutamate, serine, isoleucine, methionine, threonine, proline and valine) and glucose alongside with increased levels of fatty acids such as palmitelaidate, oleate, trans-9-octadecenoate,cis-5,8,11-eicosatrienoate, docosahexaenoate, 2-ketoisocaproateand 3-methyl-2-oxovalerate and cholesterol. This demonstrates perturbations in several bioenergetic pathways such as glycolysis, fatty acid and amino acid metabolism and other related metabolic pathways such as TCA cycle, thus suggesting a pivotal role of metabolic perturbations in the pathogenesis of RA.
Metabolic defects have been found in autoimmune disorders other than RA. For instance, systemic lupus erythematosus (SLE) CD4+ T cells display a metabolic dysregulation in both humans and mice. Specifically CD4+ T cells from SLE patients exhibit enhanced glycolysis and mitochondrial metabolism that correlate with their activation status (65, 66). Inhibition of these pathways (with 2-deoxyglucose and metformin, respectively) reduced IFN-γ production in vitro and normalized T-cell metabolism and disease phenotypes in vivo. Moreover, mitochondrial membrane hyperpolarization led to increased activity of the mammalian target of rapamycin (mTOR) in CD4+ T cells from SLE patients (65, 66) and rapamycin treatment reduced disease manifestations in these patients (67, 68). In contrast, a metabolomics study on SLE sera revealed reduced glycolysis, Krebs cycle, fatty acid  oxidation and amino acid metabolism in these patients compared to healthy controls. This dysregulation associates with dampened energy generation, high oxidative stress, inflammation, altered lipid profiles and a prothrombotic state (69). Furthermore, serum levels of total LDH, LDH1 and LDH2 were significantly higher in patients with diffuse proliferative lupus nephritis and showed good correlations with the activity index and the total pathologic score of the renal pathologic scoring system, and with the glomerular hyper-cellularity. This suggests a possible role of this enzyme as biomarker for disease progression (70).
	A bioenergetic deregulation has also been associated to multiple sclerosis (MS), a chronic inflammatory disease, which leads to focal plaques of demyelination and tissue injury in the CNS.  A mitochondrial dysfunction with defects of mitochondrial respiratory chain complex IV [cytochrome c oxidase (COX)] has been found in some active lesions of relapsing remitting MS patients (71). Furthermore, a metabolomic study has revealed changes in MS patient serum levels of different metabolites and oxidants/antioxidants unbalance compared to healthy controls (72). Moreover, increased levels of both glutamine and glutamate have been described. Glutamate concentration correlates with disease severity and glutamine is critically required for naive CD4+ T-cell differentiation toward Th1 and Th17 pro-inflammatory T cells (72). De Rosa et al recently found that glycolysis is required for the expression of FOXP3 (forkhead box P3), a master regulator in the development and suppressive function of Treg cells (73). MS subjects display impaired rates of glycolysis, which in turn determines altered peripheral Treg-cell generation and functions (73). Conversely, other authors found increased extra-mitochondrial glucose metabolism in the cerebrospinal fluid (CSF) (74) as well as in the serum of MS patients with higher levels of lactate as compared to controls (75, 76). These parameters were positively correlated and associated with disease progression and activity (75, 76). 

Concluding remarks
The mechanisms underpinning the crosstalk between the immune system and metabolism have been intensively studied for the last few years.  As the metabolite produced at the end of glycolysis, lactate is emerging as an important signaling molecule promoting specific immune-inflammatory responses. The discovery of specific lactate transporters on the surface of immune cells has opened novel and important perspectives for the understanding of the pathogenesis of inflammatory and autoimmune disorders. Targeting these molecules might prove crucial in the modulation of immune cell functions to achieve beneficial therapeutic effects.
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Figure 1.  Lactate accumulates in synovial joints of RA patients and modulates T-cell functions. Lactate accumulates in the synovial joints during inflammation, where is in part responsible of the acidic environment. Here T cells sense high concentrations of lactate via their specific carriers, the sodium lactate transporter SLC5A12 in CD4+ T cells and the lactic acid transporter SLC16A1 in CD8+ T cells. Via this interaction lactate inhibits T-cell motility by interfering with the glycolytic pathway, which is important for T-cell migration. Loss of motility leads to T-cell entrapment in the synovial joint, where CD4+ T cells produce high amounts of IL-17 and CD8+ T cells lose their cytolytic activity. Increased retention of CD4+ T cells accompanied by increased local levels of IL-17 might in turn be responsible of the formation of ELSs.
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